The Ministry of Health and Welfare and the National Clinical Research Center held the '2026 World Clinical Trials Day' commemorative event on June 20th, prominently featuring global clinical trial collaboration as this year's core message. This event is interpreted as more than just a commemoration; it officially marks a strategic shift for Korean clinical trials. The government emphasized that AI-based clinical trial technology, the utilization of digital medical data, and the invigoration of international joint research will determine national competitiveness in the future. Approximately 100 attendees, including pharmaceutical companies, hospitals, and patient organizations, participated in the event, and 15 individuals who contributed to the advancement of clinical trials were awarded ministerial commendations. This signifies that Korea views clinical trials not merely as a research stage but as a core infrastructure for the bio-industry. The most notable aspect of this announcement is the AI transformation (AX) of clinical trials. To respond to changes in the global environment, the government stated its commitment to continue policy support, including AI-driven clinical design, the establishment of a clinical ecosystem centered on chronic diseases, and the nurturing of domestic CROs. This signals to domestic companies that the era of simply having good pipelines is over; instead, clinical execution capabilities and data processing capabilities are directly linked to corporate value. In particular, the message that network-based collaboration is becoming more important than competition at the hospital level suggests that the Korean clinical trial market may evolve into a more sophisticated platform competition. Ultimately, the essence of today's news is not merely that an event was held, but a declaration that Korea's clinical trial system is being upgraded to be more global and digitally focused. For pharmaceutical and bio companies, those that preemptively secure elements such as attracting multinational clinical trials, patient recruitment based on medical data, and AI analysis integration are likely to gain a greater advantage. It is also important that opportunities can expand across hospitals, CROs, data companies, and AI medical companies. From a future-oriented perspective, for Korea to become a powerhouse in new drug development, it must elevate not only its candidate substances but also its clinical infrastructure to an exportable level. This event is close to that starting point.